Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Next Previous
X
Search
Trial Profile

A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vamorolone (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ReveraGen BioPharma

    • Most Recent Events

    • 10 Oct 2022 According to a Santhera Pharmaceuticals media release, data from this trial will be shared at the 2022 World Muscle Society (WMS) Congress.
    • 09 Jun 2022 According to a Santhera Pharmaceuticals media release, data will be presented during the poster session at the 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD).
    • 28 Apr 2021 Results (new clinical data of 2.5-year treatment outcome) presented in a Santhera Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top